2023 World Conference on Lung Cancer (Posters)-EP12.01. Aumolertinib Combination SBRT Treated EGFR Co-mutation Patients with Symptomatic Brain Metastases: A Case Report

EP12.01. Aumolertinib Combination SBRT Treated EGFR Co-mutation Patients with Symptomatic Brain Metastases: A Case Report - PDF(Slides)

Back to course

Pdf Summary

A case report from The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital in China describes the treatment of a 79-year-old male patient with EGFR co-mutation and symptomatic brain metastases. The patient had advanced lung cancer and had previously been treated with the third-generation EGFR-TKI osimertinib, but the treatment failed to control the progression of lung lesions. The patient also experienced continuous headaches during osimertinib re-challenge. <br /><br />The case report then discusses the use of aumolertinib, another third-generation EGFR-TKI, in combination with stereotactic body radiation therapy (SBRT) to treat the patient's symptomatic brain metastases. Aumolertinib was found to improve the patient's neurological symptoms and resulted in a partial response without obvious neurological symptoms. The patient experienced a progression-free survival of 12.1 months and an overall survival of 20.6 months before eventually succumbing to the disease. <br /><br />The report concludes that the combination of aumolertinib and local therapy, such as SBRT, can improve neurological symptoms and prolong survival in patients with symptomatic brain metastases. However, further studies with larger sample sizes are needed to confirm the efficacy of EGFR-TKI treatment in this patient population.

Asset Subtitle

Xiaojuan Zhang

Meta Tag

Speaker Xiaojuan Zhang

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

case report

EGFR co-mutation

symptomatic brain metastases

advanced lung cancer

third-generation EGFR-TKI

osimertinib

aumolertinib

stereotactic body radiation therapy

neurological symptoms

progression-free survival